The fate of (−)1-(benzofuran-2-yl)-2-propylaminopentane · HCl, (−)-BPAP, in rats, a potent enhancer of the impulse-evoked release of catecholamines and serotonin in the brain

@article{Magyar2010TheFO,
  title={The fate of (−)1-(benzofuran-2-yl)-2-propylaminopentane · HCl, (−)-BPAP, in rats, a potent enhancer of the impulse-evoked release of catecholamines and serotonin in the brain},
  author={K. Magyar and J. Lengyel and A. Bolehovszky and B. Knoll and Iidik{\'o} Miklya and J. Knoll},
  journal={European Journal of Drug Metabolism and Pharmacokinetics},
  year={2010},
  volume={27},
  pages={157-161}
}
  • K. Magyar, J. Lengyel, +3 authors J. Knoll
  • Published 2010
  • Chemistry, Medicine
  • European Journal of Drug Metabolism and Pharmacokinetics
    • SummaryOur aim was to study the fate of (−)-1-(benzofuran-2-yl)-2-propylaminopentane · HCl [(−)-BPAP] in rats, using radio-labelled compound [(−)-BPAP-14C]. Radioactivity was measured by liquid scintillation technique and the tissue concentrations of radioactivity were calculated on the basis of the specific activity of (−)-BPAP-14C and the values are given in ngeq./g.Radioactivity was well absorbed after i.p., s.c. and oral treatment and Cmax has been reached at 30 to 60 min following drug… CONTINUE READING
    View on Springer
    ncbi.nlm.nih.gov
    Top 1 of 1 Citations
    A tryptamine-derived catecholaminergic enhancer, (−)-1-(benzofuran-2-yl)-2-propylaminopentane [(−)-BPAP], attenuates reinstatement of methamphetamine-seeking behavior in rats
    T. Hiranita, T. Yamamoto, Y. NawataNeuroscience2010
    7

    Figures, Tables, and Topics from this paper.

    Figures and Tables

    Explore Further: Topics Discussed in This Paper

    One Citation
    Citation Type

    Citation Type

    A tryptamine-derived catecholaminergic enhancer, (−)-1-(benzofuran-2-yl)-2-propylaminopentane [(−)-BPAP], attenuates reinstatement of methamphetamine-seeking behavior in rats
    • 7

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 10 REFERENCES
    (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons.
    • 49
    Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
    • 34
    (−)1‐(Benzofuran‐2‐yl)‐2‐propylaminopentane, [(−)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain
    • 45
    (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
    • 70
    Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain.
    • 31
    Enantioselective synthesis and absolute configuration of (-)-1-(benzofuran-2-yl)-2-propylaminopentane, ((-)-BPAP), a highly potent and selective catecholaminergic activity enhancer.
    • 18
    Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain.
    • 56
    -)Deprenyl and (-) l-phenyl-z-propylaminopentane, [(-)pPAP]. act primarily as potent stimulants of action potential- transmitter release coupling in the catecholaminergic neurones
    • 1996
    Deprenyl : the anti - aging psychoenergizer
    • 2001
    Outlines of a drug strategy to slow brain aging
    • 2000